Payment overview · 2025
General Payments
$1,768.13
44 reported records · 13 companies
Healthcare provider profile · identity verified
Philip Kim, MD
Allopathic & Osteopathic Physicians|Family Medicine · TORRANCE, CA · NPI 1356781132
Verified facts
What the public records show
CMS Open Payments records show Philip Kim, MD received $1,768.13 in general payments during 2025 across 44 reported records.
Envista Holdings Corporation accounted for 42.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Gemtesa, Jardiance, Linzess, Ozempic, Paxlovid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Prolia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Envista Holdings Corporation | Unresolved — no canonical attribution shown | $750.00 | 42.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $270.89 | 15.3% | 13 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $173.73 | 9.8% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $133.82 | 7.6% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $95.78 | 5.4% | 4 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $54.11 | 3.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $50.80 | 2.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $48.31 | 2.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $47.79 | 2.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $46.97 | 2.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $43.74 | 2.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.17 | 1.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.02 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,018.13 | 43 |
| Consulting Fee | $750.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EDUCATION Normalized: education |
Device | Envista Holdings Corporation | $750.00 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $177.42 | 7 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $177.42 | 7 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $173.73 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $81.76 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $71.26 | 3 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $54.11 | 2 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $54.11 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $52.17 | 2 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $51.37 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $48.31 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $48.31 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $47.89 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $46.97 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $43.74 | 2 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $28.11 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $27.89 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $27.89 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $27.89 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $26.05 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $24.79 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $24.79 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $24.52 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.02 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $5.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 71 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 107 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 27 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 13 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
71 | 23 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
27 | 11 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
28 | 21 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
107 | 37 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
107 | 37 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
30 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 12 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 556 | 212 |
| Amlodipine Besylate | Amlodipine Besylate | 400 | 155 |
| Losartan Potassium | Losartan Potassium | 384 | 140 |
| Azithromycin | Azithromycin | 304 | 219 |
| Metformin Hcl | Metformin Hcl | 290 | 105 |
| Omeprazole | Omeprazole | 259 | 112 |
| Ibuprofen | Ibuprofen | 250 | 162 |
| Tamsulosin Hcl | Tamsulosin Hcl | 233 | 92 |
| Escitalopram Oxalate | Escitalopram Oxalate | 214 | 72 |
| Simvastatin | Simvastatin | 168 | 68 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 167 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 165 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 165 | 64 |
| Levothyroxine Sodium | Levothyroxine Sodium | 162 | 66 |
| Donepezil Hcl | Donepezil Hcl | 148 | 45 |
| Vascepa | Icosapent Ethyl | 143 | 38 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 139 | 89 |
| Famotidine | Famotidine | 131 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 127 | 47 |
| Meloxicam | Meloxicam | 124 | 36 |
| Metformin Hcl Er | Metformin Hcl | 119 | 40 |
| Jardiance | Empagliflozin | 107 | 37 |
| Furosemide | Furosemide | 99 | 34 |
| Gabapentin | Gabapentin | 96 | 46 |
| Alendronate Sodium | Alendronate Sodium | 95 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 91 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 90 | 41 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 87 | 67 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 51 |
| Januvia | Sitagliptin Phosphate | 77 | 17 |
| Icosapent Ethyl | Icosapent Ethyl | 74 | 20 |
| Amoxicillin | Amoxicillin | 72 | 53 |
| Creon | Lipase/Protease/Amylase | 71 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 69 | 28 |
| Finasteride | Finasteride | 68 | 25 |
| Lidocaine | Lidocaine | 66 | 30 |
| Lisinopril | Lisinopril | 63 | 28 |
| Myrbetriq | Mirabegron | 62 | 20 |
| Tramadol Hcl | Tramadol Hcl | 62 | 33 |
| Glipizide | Glipizide | 61 | 25 |
| Latanoprost | Latanoprost | 53 | 14 |
| Meclizine Hcl | Meclizine Hcl | 53 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 17 |
| Azelastine Hcl | Azelastine Hcl | 47 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 19 |
| Glipizide Er | Glipizide | 47 | 16 |
| Ketoconazole | Ketoconazole | 47 | 15 |
| Celecoxib | Celecoxib | 43 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 27 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | 13 |
| Pregabalin | Pregabalin | 39 | 22 |
| Fenofibrate | Fenofibrate | 38 | 13 |
| Hydrocortisone | Hydrocortisone | 38 | 21 |
| Raloxifene Hcl | Raloxifene Hcl | 38 | 15 |
| Trazodone Hcl | Trazodone Hcl | 38 | 18 |
| Valacyclovir | Valacyclovir Hcl | 38 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 37 | 19 |
| Alprazolam | Alprazolam | 34 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 34 | 13 |
| Fluocinonide | Fluocinonide | 34 | 20 |
| Levofloxacin | Levofloxacin | 32 | 25 |
| Mupirocin | Mupirocin | 31 | 24 |
| Nifedipine Er | Nifedipine | 31 | 12 |
| Eliquis | Apixaban | 30 | 16 |
| Lorazepam | Lorazepam | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | 12 |
| Prolia | Denosumab | 28 | 21 |
| Linzess | Linaclotide | 27 | 11 |
| Methocarbamol | Methocarbamol | 27 | 23 |
| Temazepam | Temazepam | 27 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 26 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 26 | suppressed |
| Ozempic | Semaglutide | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 16 |
| Carvedilol | Carvedilol | 24 | 12 |
| Clotrimazole | Clotrimazole | 24 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 24 | 11 |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 23 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 14 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Tadalafil | Tadalafil | 22 | suppressed |
| Tavaborole | Tavaborole | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 20 |
| Clonazepam | Clonazepam | 21 | suppressed |
| Ofloxacin | Ofloxacin | 21 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 20 |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Allopurinol | Allopurinol | 20 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 20 | 15 |
| Sildenafil Citrate | Sildenafil Citrate | 20 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Loperamide | Loperamide Hcl | 19 | 16 |
| Megestrol Acetate | Megestrol Acetate | 19 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 19 | suppressed |
| Prednisone | Prednisone | 19 | 17 |
| Ciclopirox | Ciclopirox | 18 | 13 |
| Restasis | Cyclosporine | 18 | 12 |
| Timolol Maleate | Timolol Maleate | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | 11 |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Erythromycin | Erythromycin Base | 15 | 15 |
| Gemtesa | Vibegron | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Procto-Med Hc | Hydrocortisone | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 11 | suppressed |
| Misoprostol | Misoprostol | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Potassium Chloride | Potassium Chloride | 11 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,768.13 · 44 records | Envista Holdings Corporation | ABRYSVO, AREXVY, Arikayce, BOTOX, Brinsupri, COMIRNATY, CREON, Cologuard Collection Kit, DALVANCE, Dexcom G6 Transmitter, EDUCATION, GEMTESA, JARDIANCE, Kerendia, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, VIBERZI, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error